Jun 17 |
Nurix releases promising phase 1 data on NX-5948 for chronic lymphocytic leukemia
|
Jun 16 |
Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) at the European Hematology Association Congress (EHA2024)
|
Jun 12 |
Nurix Therapeutics files for mixed shelf securities offering
|
Jun 10 |
Nurix Therapeutics to Host a Webcast and Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of NX-5948 Being Presented at the European Hematology Association Congress (EHA2024)
|
May 29 |
Nurix Therapeutics to Participate in the Jefferies Global Healthcare Conference
|
May 28 |
Nurix Therapeutics appoints Paula O’Connor as chief medical officer
|
May 28 |
Nurix Therapeutics Appoints Paula G. O’Connor, M.D., as Chief Medical Officer and Pasit Phiasivongsa, Ph.D., as Chief Technical Officer
|
May 20 |
Nurix Therapeutics announces Julia P. Gregory as new board Chair
|
May 20 |
Nurix Therapeutics Announces Board Chair Transition
|
May 20 |
Nurix Therapeutics (NRIX) Moves 7.7% Higher: Will This Strength Last?
|